Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up.

ABSTRACT:

SUBMITTER: Dreyling M 

PROVIDER: S-EPMC9010121 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature